Abstract
Background: Lung cancer is one of the most deadliest worldwide. Its histologic classification is decisive to select a treatment, that is why having specific biomarkers that allow rapid typing can help to select the best treatment of this disease.
Objective: To search for novel biomarkers to differentiate among different lung cancers, and for making a prognosis of the evolution of each cancer.
Methods: Samples of Small Cell Lung Cancer (SCLC), lung adenocarcinoma (LAC) and Squamous Cell Cancer (SCC) have been RNA-seq sequenced. Genes differentially expressed have been searched and its prognosis value have been studied.
Results: We have found 945 differentially expressed genes in common in the three cancers, with seven being selected as potential biomarkers, two (ADCYAP1 and TUBA1A) for diagnosing SCLC, five (CAPN8-2, IYD, MUC1, SLC44A4 and TMC5) for diagnosing LAC and none for SCC. The five LAC biomarkers were confirmed in an external database (GEPIA, Gene Expression Profiling Interactive Analysis).
After testing those in a database containing survival data from more than 600 LAC patients, six (ADCYAP1, TUBA1A, CAPN8-2, IYD, TMC5 and MUC1) are found to have a significative prognosis value for LAC.
Conclusion: This work presents seven potential biomarkers to differentiate LAC, SCLC and SCC, two for diagnosing SCC and five to diagnose LAC. Also, six of them have prognosis value in LAC.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA3662.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019